Drug Profile
Research programme: cancer therapeutics - Supratek Pharma
Alternative Names: SP-1014C; SP-1030C; SP-1031C; SP-1063CLatest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Supratek Pharma
- Class
- Mechanism of Action Alkylating agents; DNA topoisomerase I inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; Colorectal cancer; Haematological malignancies; Non-Hodgkin's lymphoma; Prostate cancer
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Chronic lymphocytic leukaemia in Canada (Parenteral) (Supratek Pharma website, February 2023)
- 23 Feb 2023 Discontinued - Preclinical for Colorectal cancer in Canada (Parenteral) (Supratek Pharma website, February 2023)
- 23 Feb 2023 Discontinued - Preclinical for Haematological malignancies in Canada (Parenteral) (Supratek Pharma website, February 2023)